Sometimes, being the “squeaky wheel” is the only way to make a positive change.
Site Search
Cystic Fibrosis Foundation Therapeutics Inc. made its first major award last month to advance gene editing research in cystic fibrosis. Editas Medicine Inc. will explore the potential of using what some scientists refer to as “a tiny pair of scissors” to snip out the genetic defect that causes CF.
Dr. James Chmiel shares new developments in drugs to reduce inflammation in the lungs and help prevent lung damage.
The Cystic Fibrosis Foundation is funding research into gene editing techniques to see if they can be used to fix the mutations that cause cystic fibrosis. One of the most popular techniques is CRISPR-Cas9. To see how this might work for CF, watch this video.
Before you can walk a mile in a person with CF's shoes, you have to put on a nebulizer.
Connie Richless, an adult CF nurse coordinator, has seen a lot of changes in her past 22 years of working with CF patients.
In the third plenary of NACFC, three guidelines authors announced the publication of guidelines for screening and treating depression and anxiety, and explained how the guidelines were developed. Read on for my thoughts.
Hear from John P. Clancy, M.D., the first plenary speaker at this year's NACFC, about recent advances in personalized medicine, which could allow clinicians to better tailor treatment to the individual with CF.
I felt unrelenting hope watching the first plenary of this year’s North American Cystic Fibrosis Conference. As I learned about progress that has been made in sickle cell disease, and how those learnings may help us develop a genetic therapy for CF, it showed me that the CF community is supporting people like me who can’t take modulators.
There's a lot of buzz around personalized medicine, but what does it really mean? In the first plenary at NACFC, John P. Clancy, M.D., outlined the history of personalized medicine, where we are now and what the future holds. Read on for a quick recap.